Publication
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugTamoxifencivic_curation1.00
- geneTP53civic_curation1.00
- variantTP53 DNA Binding Domain Mutationcivic_curation1.00
- variantTP53 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 10786679
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TP53 DNA Binding Domain Mutation1 | ||||||||
| Tamoxifen | Malignant Breast Neoplasm | Predictive | B | Supports Resistance | 3 | accepted | EID2783In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response … (full text at CIViC) PMID 10786679 · Berns et al., 2000 · Open in CIViC | civic |
| TP53 L3 Domain Mutation1 | ||||||||
| Tamoxifen | Malignant Breast Neoplasm | Predictive | B | Supports Resistance | 3 | submitted | EID3036In a study of 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population, a 66% response rate was reported, where respo… (full text at CIViC) PMID 10786679 · Berns et al., 2000 · Open in CIViC | civic |
| TP53 Mutation1 | ||||||||
| Tamoxifen | Malignant Breast Neoplasm | Predictive | C | Supports Resistance | 1 | accepted | EID2784In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31… (full text at CIViC) PMID 10786679 · Berns et al., 2000 · Open in CIViC | civic |
| TP53 R273H1 | ||||||||
| Tamoxifen | Malignant Breast Neoplasm | Predictive | C | Supports Resistance | — | submitted | EID2289In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31… (full text at CIViC) PMID 10786679 · Berns et al., 2000 · Open in CIViC | civic |